TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways
Qiang-bo Zhang, Hong Wang, Fei Xu, Yan Song, Run-de Jiang, Qi Li, En-yu Liu · 2024
Read TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways by Qiang-bo Zhang, Hong Wang, Fei Xu, Yan Song, Run-de Jiang, Qi Li, En-yu Liu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11531577.txt.
Description
Background Sorafenib is a standard therapeutic agent for advanced hepatocellular carcinoma (HCC). However, its efficacy is moderate, as the survival of patients is prolonged for only a few months, and the response rate is low. The mechanism of low efficacy remains unclear.
Catalog record
| CREATOR | Qiang-bo Zhang, Hong Wang, Fei Xu, Yan Song, Run-de Jiang, Qi Li, En-yu Liu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |